Nephrology Dialysis Transplantation

Introduction
pp. iii1-iii1(1)
Authors: Kurokawa K.; Fukagawa M.

Control of parathyroid cell growth by calcimimetics
pp. iii13-iii17(1)
Authors: Wada M.; Nagano N.

Adenovirus-mediated functional gene transfer into parathyroid cells in vivo and in vitro
pp. iii18-iii22(1)
Authors: Iwasaki Y.; Kakuta T.; Haruguchi H.; Fukuda N.; Kurokawa K.; Fukagawa M.

Medical management of secondary hyperparathyroidism in chronic renal failure
pp. iii2-iii8(1)
Author: Goodman W.G.

Role of parathyroid intervention in the management of secondary hyperparathyroidism
pp. iii23-iii26(1)
Authors: Fukagawa M.; Nakanishi S.

Ultrasonographic diagnosis of parathyroid glands and percutaneous ethanol injection therapy
pp. iii27-iii30(1)
Author: Kitaoka M.

Guidelines for percutaneous ethanol injection therapy of the parathyroid glands in chronic dialysis patients
pp. iii31-iii33(1)
Authors: Fukagawa M.; Kitaoka M.; Tominaga Y.; Akizawa T.; Kakuta T.; Onoda N.; Koiwa F.; Yumita S.; Kurokawa for the Japanese Society for Parathyroid Intervention K.

Evaluation of blood supply to the parathyroid glands in secondary hyperparathyroidism compared with histopathology
pp. iii34-iii37(1)
Authors: Onoda N.; Kurihara S.; Sakurai Y.; Owada K.; Osono E.; Adachi H.; Suga M.; Yoneshima H.

Percutaneous calcitriol injection therapy (PCIT) for secondary hyperparathyroidism: multicentre trial
pp. iii38-iii41(1)
Authors: Kitaoka M.; Onoda N.; Kitamura H.; Koiwa F.; Tanaka M.; Fukagawa M.

Effect of percutaneous calcitriol injection therapy on secondary hyperparathyroidism in uraemic patients
pp. iii42-iii46(1)
Authors: Shiizaki K.; Negi S.; Mizobuchi M.; Hatamura I.; Narukawa N.; Sakaguchi T.; Kitabata Y.; Sumikado S.; Akizawa T.

Efficacy of direct injection of calcitriol into the parathyroid glands in uraemic patients with moderate to severe secondary hyperparathyroidism
pp. iii47-iii49(1)
Authors: Nakanishi S.; Yano S.; Nomura R.; Tsukamoto T.; Shimizu Y.; Shin J.; Fukagawa M.

Surgical verification of percutaneous maxacalcitol injection therapy on enlarged parathyroid glands in chronic dialysis patients
pp. iii50-iii52(1)
Authors: Yamamoto H.; Katoh N.; Takeyama H.; Ikeda M.; Yokoyama K.; Shigematsu T.; Kawaguchi Y.; Hosoya T.

Time course of change in calcium × phosphorus product after percutaneous ethanol injection therapy
pp. iii53-iii57(1)
Authors: Koiwa F.; Hasegawa T.; Kojima I.; Ideura T.

Long-term (3 years) prognosis of parathyroid function in chronic dialysis patients after percutaneous ethanol injection therapy guided by colour Doppler ultrasonography
pp. iii58-iii61(1)
Authors: Tanaka R.; Kakuta T.; Fujisaki T.; Tanaka S.; Sakai H.; Kurokawa K.; Saito A.

Intervention for recurrent secondary hyperparathyroidism from a residual parathyroid gland
pp. iii62-iii64(1)
Author: Yumita S.

Re-operation is frequently required when parathyroid glands remain after initial parathyroidectomy for advanced secondary hyperparathyroidism in uraemic patients
pp. iii65-iii70(1)
Authors: Tominaga Y.; Katayama A.; Sato T.; Matsuoka S.; Goto N.; Haba T.; Hibi Y.; Numano M.; Ichimori T.; Uchida K.

Long-term prognosis of parathyroid function for chronic dialysis patients after minimally invasive radioguided parathyroidectomy (MIRP)
pp. iii71-iii75(1)
Authors: Kakuta T.; Suzuki Y.; Tadaki F.; Tanaka R.; Tanaka S.; Sakai H.; Kurokawa K.; Saito A.

Combined radioguided parathyroidectomy and intravenous vitamin D therapy for the treatment of uraemic hyperparathyroidism
pp. iii76-iii78(1)
Authors: Oyama Y.; Kazama J.J.; Maruyama H.; Narita I.; Kanbayashi C.; Koyama Y.; Omori T.; Hatakeyama K.; Gejyo F.

Molecular targets of hyperphosphataemia in chronic renal failure
pp. iii79-iii80(1)
Authors: Miyamoto K-I.; Ito M.; Segawa H.; Kuwahata M.

Sevelamer hydrochloride, a calcium-free phosphate binder, inhibits parathyroid cell proliferation in partially nephrectomized rats
pp. iii81-iii85(1)
Authors: Nagano N.; Miyata S.; Obana S.; Kobayashi N.; Abe M.; Fukushima N.; Wada M.

Phosphate overload accelerates vascular calcium deposition in end-stage renal disease patients
pp. iii86-iii89(1)
Authors: Shigematsu T.; Kono T.; Satoh K.; Yokoyama K.; Yoshida T.; Hosoya T.; Shirai K.

Parathyroid cell growth in patients with advanced secondary hyperparathyroidism: vitamin D receptor and cyclin-dependent kinase inhibitors, p21 and p27
pp. iii9-iii12(1)
Authors: Tokumoto M.; Tsuruya K.; Fukuda K.; Kanai H.; Kuroki S.; Hirakata H.; Iida M.

Colestimide can be used as a phosphate binder to treat uraemia in end-stage renal disease patients
pp. iii90-iii93(1)
Authors: Date T.; Shigematsu T.; Kawashita Y.; Satake N.; Morita K.

Role of osteoclastic dysfunction in the development of renal bone disease
pp. iii94-iii96(1)
Authors: James Kazama J.; Gejyo F.; Kurosawa T.; Fukagawa M.

IRMA (whole PTH) is a more useful assay for the effect of PTH on bone than the Allegro intact PTH assay in CAPD patients with low bone turnover marker
pp. iii97-iii98(1)
Authors: Tanno Y.; Yokoyama K.; Nakayama M.; Katoh A.; Yamamoto H.; Iwasaki Y.; Cantor T.; Fukagawa M.; Shigematsu T.; Hosoya T.